Journal of geriatric oncology · 2026
Economic impact of preoperative frailty in patients undergoing cytoreductive surgery.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bai Zirong, Barker Laura, Koh Cherry, Solomon Michael, Shahab Rihan, Alexander Kate, Karunaratne Sascha, Ansari Nabila, Pereira Leani Souza Maximo, Lage Ana Paula Drummond, Steffens Daniel
Аннотация
INTRODUCTION: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) is a complex and costly treatment for peritoneal surface malignancies. While preoperative frailty is known to worsen postoperative outcomes, its economic impact in CRS + HIPEC remains underexplored. This study evaluated the association between preoperative frailty and in-hospital costs in this population.
MATERIALS AND METHODS: A retrospective cohort study was conducted at a tertiary center in Sydney, Australia, including adults who underwent CRS + HIPEC from May 2017 to June 2024. Frailty was assessed using the Clinical Frailty Scale (CFS), with scores of 4 or higher classified as frail. Patient characteristics, surgical outcomes, and in-hospital cost data, including staff, intensive care, diagnostics, theatre, ward, and other services, were collected. Mann-Whitney U tests and chi-square tests were used for comparisons. Multivariable linear regression identified cost drivers in frail patients.
RESULTS: Among 466 patients, 60 (12.9%) were classified as frail. Frail patients were significantly older than non-frail patients. Cost differences were particularly evident in staffing, diagnostics, and ward-related care, with frail patients incurring higher expenses across all categories. Total in-hospital costs were significantly higher in frail compared to non-frail patients (median AU$115,282 vs AU$106,938; p = 0.005). Multivariate analysis identified intensive care unit stay as the primary driver of total in-hospital cost within the frail cohort.
DISCUSSION: Preoperative frailty is independently associated with increased in-hospital costs among patients undergoing CRS + HIPEC. These findings highlight the value of incorporating frailty assessment into preoperative evaluation and suggest a need for targeted perioperative strategies to optimise outcomes and resource use in frail surgical populations.
MATERIALS AND METHODS: A retrospective cohort study was conducted at a tertiary center in Sydney, Australia, including adults who underwent CRS + HIPEC from May 2017 to June 2024. Frailty was assessed using the Clinical Frailty Scale (CFS), with scores of 4 or higher classified as frail. Patient characteristics, surgical outcomes, and in-hospital cost data, including staff, intensive care, diagnostics, theatre, ward, and other services, were collected. Mann-Whitney U tests and chi-square tests were used for comparisons. Multivariable linear regression identified cost drivers in frail patients.
RESULTS: Among 466 patients, 60 (12.9%) were classified as frail. Frail patients were significantly older than non-frail patients. Cost differences were particularly evident in staffing, diagnostics, and ward-related care, with frail patients incurring higher expenses across all categories. Total in-hospital costs were significantly higher in frail compared to non-frail patients (median AU$115,282 vs AU$106,938; p = 0.005). Multivariate analysis identified intensive care unit stay as the primary driver of total in-hospital cost within the frail cohort.
DISCUSSION: Preoperative frailty is independently associated with increased in-hospital costs among patients undergoing CRS + HIPEC. These findings highlight the value of incorporating frailty assessment into preoperative evaluation and suggest a need for targeted perioperative strategies to optimise outcomes and resource use in frail surgical populations.